The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901YOX" target="_blank" >RIV/61988987:17110/18:A1901YOX - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/18:00105233 RIV/65269705:_____/18:00070331 RIV/00843989:_____/18:E0107219
Result on the web
<a href="http://dx.doi.org/10.21873/anticanres.12828" target="_blank" >http://dx.doi.org/10.21873/anticanres.12828</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.12828" target="_blank" >10.21873/anticanres.12828</a>
Alternative languages
Result language
angličtina
Original language name
The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma
Original language description
Background/Aim: Monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma often precede multiple myeloma (MM). The identification of biomarkers predicting progression to MM might facilitate an earlier diagnosis of MM. Our study assessed the diagnostic value of plasma levels of endocan, a 50-kDa soluble dermatan sulfate proteoglycan produced and secreted by endothelial cells, hitherto unknown in MM, in patients with plasma cell dyscrasia. Materials and Methods: Endocan levels were determined in 96 peripheral blood plasma samples by sandwich enzyme-linked immunosorbent assay (ELISA) in healthy controls (n=12), in patients with MGUS (n=17), and in patients newly diagnosed with (n=42) or relapsed/refractory (n=25) MM. Results: Median endocan concentration increased from MGUS (315.00 pg/ml) and healthy controls (316.19 pg/ml) to newly-diagnosed MM (371.82 pg/ml; p=0.027). The low endocan levels (median=246 .20 pg/ml) in patients with relapsed/refractory MM were similar to those in healthy controls and patients with MG US. A cut-off value of >220 pg/ml endocan in peripheral blood discriminated patients newly diagnosed with MM from those with MGUS (area under the curve(AUC)=0.66, 95% confidence interval(CI)=0.55-0.81). Conclusion: The plasma levels of endocan can non-invasively differentiate patients newly diagnosed with MM from those with MGUS and should therefore be evaluated prospectively as a potential diagnostic marker.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Anticancer Research
ISSN
0250-7005
e-ISSN
—
Volume of the periodical
38
Issue of the periodical within the volume
9
Country of publishing house
GR - GREECE
Number of pages
6
Pages from-to
5087-5092
UT code for WoS article
000449957600014
EID of the result in the Scopus database
2-s2.0-85052985599